52 results
8-K
EX-99.1
NUVL
Nuvalent, Inc.
17 Sep 24
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
4:21pm
), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced … targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential
424B5
NUVL
Nuvalent, Inc.
17 Sep 24
Prospectus supplement for primary offering
4:13pm
of existing therapies for clinically proven kinase targets.
Limitations faced by currently available kinase inhibitors can include (i) kinase resistance … for existing therapies to inhibit other structurally similar kinase targets and lead to off-target adverse events, and (iii) limited brain penetrance
424B5
NUVL
Nuvalent, Inc.
16 Sep 24
Prospectus supplement for primary offering
7:16am
for clinically proven kinase targets.
Limitations faced by currently available kinase inhibitors can include (i) kinase resistance, or the emergence … to inhibit other structurally similar kinase targets and lead to off-target adverse events, and (iii) limited brain penetrance, or the ability
8-K
EX-99.1
NUVL
Nuvalent, Inc.
16 Sep 24
Other Events
6:05am
company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted the presentation of updated … precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets
8-K
EX-99.1
jcoec
8 Aug 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
6:41am
8-K
EX-99.1
udw1l4 j4w
9 May 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
6:37am
8-K
EX-99.1
e13hwc6 stjawqh
27 Feb 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
6:38am
8-K
EX-99.1
16owt iwfbapygq
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
8-K
EX-99.1
a90yftxz9 vt0
14 Nov 23
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
6:45am
8-K
EX-99.1
u5rjpamhpkv 5kpsf
17 Oct 23
Nuvalent Announces Pricing of Public Offering of Common Stock
4:07pm
424B5
36c5o7b rszgh
17 Oct 23
Prospectus supplement for primary offering
4:05pm
424B5
hx7w2d
16 Oct 23
Prospectus supplement for primary offering
7:39am
8-K
EX-99.1
8zi vcqa1awhklzoc
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
odlxx86y47 5famyj7
4 Oct 23
Other Events
4:05pm